Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta

Journal of Immunological Methods

Volumn 352, Issue 1-2, 2010, Pages 32-37

  van Beers, Miranda M C ^a,b   Sauerborn, Melody ^a   Gilli, Francesca ^c   Hermeling, Suzanne ^a   Brinks, Vera ^a   Schellekens, Huub ^a   Jiskoot, Wim ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Binding antibodies; C57Bl 6 FVB N hybrid mice; Immune tolerance; Immunogenicity; Neutralising antibodies; Recombinant human interferon beta

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; C57BL 6 MOUSE; CONTROLLED STUDY; CROSS HYBRIDIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CHIMERA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNE TOLERANCE; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYETHYLENE GLYCOLS; PROTEIN BINDING; RECOMBINANT PROTEINS;

MUS; MUS MUSCULUS;

EID: 71749100389     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.10.005     Document Type: Article

References (26)

1. Antonelli G., and Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur. Cytokine Netw. 10 (1999) 413-422
2. Baker D.P., Lin E.Y., Lin K., Pellegrini M., Petter R.C., Chen L.L., Arduini R.M., Brickelmaier M., Wen D., Hess D.M., Chen L., Grant D., Whitty A., Gill A., Lindner D.J., and Pepinsky R.B. N-terminally pegylated human interferon-β-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug. Chem. 17 (2006) 179-188
3. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., Milano E., Melis F., and Giordana M.T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 73 (2002) 148-153
4. Bertolotto A., Deisenhammer F., Gallo P., and Sorensen P.S. Immunogenicity of interferon beta: differences among products. J. Neurol. 251 Suppl 2 (2004) II15-II24
5. Braun A., Kwee L., Labow M.A., and Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm. Res. 14 (1997) 1472-1478
6. Cohen B.A., Oger J., Gagnon A., and Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J. Neurol. Sci. 275 (2008) 7-17
7. Cook S.D., Quinless J.R., Jotkowitz A., and Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 57 (2001) 1080-1084
8. EMEA. Betaferon, EPAR summary for the public. European Public Assessment Report (EPAR) online database (2006). http://www.emea.europa.eu/humandocs/PDFs/EPAR/Betaferon/059095en1.pdf http://www.emea.europa.eu/humandocs/PDFs/EPAR/Betaferon/059095en1.pdf (accessed 7 March 2009)
9. EMEA. Rebif, EPAR summary for the public. European Public Assessment Report (EPAR) online database (2009). http://www.emea.europa.eu/humandocs/PDFs/EPAR/Rebif/H-136-en1.pdf http://www.emea.europa.eu/humandocs/PDFs/EPAR/Rebif/H-136-en1.pdf (accessed 7 March 2009)
10. Gilli F., van Beers M., Marnetto F., Jiskoot W., Bertolotto A., and Schellekens H. Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. J. Immunol. Methods 336 (2008) 119-126
11. Giovannoni G., Munschauer III F.E., and Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73 (2002) 465-469
12. Hermeling S., Aranha L., Damen J., Slijper M., Schellekens H., Crommelin D., and Jiskoot W. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22 (2005) 1997-2006
13. Hermeling S., Jiskoot W., Crommelin D., Bornæs C., and Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. 22 (2005) 847-851
14. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., and Bertolotto A. Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031-2037
15. Mark D.F., Lu S.D., Creasey A.A., Yamamoto, and Lin L.S. Site-specific mutagenesis of the human fibroblast interferon gene. Proc. Natl. Acad. Sci. USA 81 (1984) 5662-5666
16. Ottesen J.L., Nilsson P., Jami J., Weilguny D., Dührkop M., Bucchini D., Havelund S., and Fogh J.M. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37 (1994) 1178-1185
17. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J. Neuroimmunol. 166 (2005) 180-188
18. Pachner A., Brady J., Steiner I., and Narayan K. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J. Neurol. 255 (2008) 1815-1817
19. Perini P., Facchinetti A., Bulina P., Massaro A.R., De Pascalis D., Bertolotto A., Biasi G., and Gallo P. Interferon-beta (INF-b) antibodies in interferon-b1a- and interferon-b1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-b immunogenicity in vivo. Eur. Cytokine Netw. 12 (2001) 56-61
20. Rosenberg A. Effects of protein aggregates: an immunologic perspective. AAPS J. 8 (2006) E501-E507
21. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., and Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15 (1998) 641-649
22. Ryan S.M., Mantovani G., Wang X., Haddleton D.M., and Brayden D.J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5 (2008) 371-383
23. Siegel J.P., and Donlon J.A. Center for Drug Evaluation and Research. Approval letter. Drugs@FDA online database (1996). http://www.fda.gov/cder/foi/appletter/1996/ifnbbio051796l.pdf http://www.fda.gov/cder/foi/appletter/1996/ifnbbio051796l.pdf (accessed 7 March 2009)
24. Sominanda A., Hillert J., and Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J. Neurol. Neurosurg. Psychiatry 79 (2008) 57-62
25. Sorensen P.S. Review: Neutralizing antibodies against interferon-beta. Ther. Adv. Neurol. Disord. 1 (2008) 125-141
26. Woodcock J. Center for Drug Evaluation and Research. Application number: 103471. Approval letter. Drugs@FDA online database (1993). http://www.fda.gov/cder/foi/nda/pre96/103471s0000_APPROV.pdf http://www.fda.gov/cder/foi/nda/pre96/103471s0000_APPROV.pdf (accessed 7 March 2009)